Odyssey Group Stock Price, News & Analysis

Odyssey Group International, Inc. (OTCQB: ODYY) has established a Scientific Advisory Board (SAB) comprising experts in neurology, cardiology, and preclinical drug development to guide the company in advancing its medical product portfolio. The SAB will assist in the development of PRV-002, a drug candidate for concussion treatment, expected to enhance R&D and clinical efforts. Founding members include prominent figures with extensive military and clinical research backgrounds, aiming to address significant medical needs.

Odyssey Group International welcomes Abby Wambach, former U.S. National Soccer Team captain, to its Sports Advisory Board to increase awareness of the need for treatments for brain injuries, including concussions. The Sports Advisory Board consists of various notable athletes working to support the company’s outreach. Odyssey is in the pre-clinical phase of developing PRV-002, a drug compound aimed at treating mild traumatic brain injuries (concussions), preparing for its first human clinical trial. CEO Michael Redmond emphasized the critical need for effective concussion treatments.

Odyssey Group International (OTCQB:ODYY) announced that CEO Michael Redmond will present at the Q1 Virtual Investor Summit on March 24, 2021, at 2:30 PM ET. The summit will feature various small- and mid-cap companies connecting with over 300 qualified investors. Redmond will discuss Odyssey's strategy regarding life-saving medical products, specifically its drug candidate PRV-002, intended for treating concussion. The event highlights Odyssey's commitment to developing innovative medical solutions.

Odyssey Group International (OTCQB: ODYY) has formed a Sports Advisory Board (SAB) to enhance awareness of brain injuries and the need for FDA-approved treatments. The SAB features prominent athletes like Kurt Warner and Brett Favre, who aim to address the issue of concussions, emphasizing the development of PRV-002, a drug currently in pre-clinical trials. CEO Michael Redmond highlighted the pressing need for effective therapies for traumatic brain injuries.

Odyssey Group International, Inc. (OTCQB:ODYY) announced that Dr. Jake VanLandingham will appear on NewsNation Now's 'The Donlon Report' with Brett Favre to discuss PRV-002, a novel treatment for concussions. The segment airs at 7:30 PM ET on March 10, 2021. Dr. VanLandingham expressed enthusiasm over the media attention PRV-002 is receiving as the company gears up for human clinical trials. PRV-002, a synthetic neurosteroid, shows promise in preclinical studies, demonstrating neuroprotective effects that could benefit those suffering from mild traumatic brain injury.

Odyssey Group International, Inc. (OTCQB:ODYY) has completed its acquisition of PRV-002, a novel neurosteroid aimed at treating concussions, from Prevacus, Inc. This all-stock transaction positions Odyssey to address a significant market opportunity, as over 3 million concussions occur annually in the U.S., with no FDA-approved drug currently available. PRV-002 has shown promise in preclinical studies, demonstrating effective brain biodistribution and positive behavioral outcomes. The company anticipates launching Phase 1 clinical trials in Q2 2021, with Dr. Jake VanLandingham leading the drug development efforts.

Odyssey Group International, Inc. (OTCQB:ODYY) has announced the successful completion of the design development phase of its Save A Life choking rescue device, in collaboration with Tanaka Kapec Design Group. The product is now transitioning to the prototyping stage, where experts will test and refine its effectiveness. The collaboration has optimized the device's design for enhanced ergonomics and usability. CEO Michael Redmond expressed enthusiasm for advancing towards FDA submission to improve outcomes for choking emergencies.

Odyssey Group International, Inc. (OTCQB:ODYY) and Prevacus Inc. announced positive pre-clinical results for PRV-002, a nasal drug aimed at treating concussions. The studies indicated that PRV-002 demonstrated rapid brain absorption, with enhanced bioavailability when formulated as nanoparticles. After nasal administration, approximately 40% more of the drug was detected in brain tissues after 8 hours compared to its native form. Odyssey is set to finalize its acquisition of PRV-002 by the end of February, contingent on shareholder approval.

Odyssey Group International, Inc. (OTCQB: ODYY) announced significant media coverage for its concussion treatment, Prevasol. Recent appearances include CheddarTV on February 5, Newsmax on February 7, and Fox Business on February 8, featuring CEO Dr. Jake VanLandingham and former NFL stars discussing brain injuries. The company is excited about its pending partnership with Prevacus, with a definitive agreement to acquire the drug candidate PRV-002 expected to close by the end of February 2021, pending shareholder approval.